These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197 [TBL] [Abstract][Full Text] [Related]
24. Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. Funch DP; Brady J; Ko HH; Dreyer NA; Walker AM Recent Results Cancer Res; 2002; 159():81-8. PubMed ID: 11785847 [TBL] [Abstract][Full Text] [Related]
25. Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience. Wójciak M; Gozdowska J; Dęborska-Materkowska D; Perkowska-Ptasińska A; Kosieradzki M; Nazarewski S; Durlik M Transplant Proc; 2018 Sep; 50(7):2154-2158. PubMed ID: 30177129 [TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota. Wudhikarn K; Holman CJ; Linan M; Blaes AH; Dunitz JM; Hertz ME; Peterson BA Clin Transplant; 2011; 25(5):705-13. PubMed ID: 21077949 [TBL] [Abstract][Full Text] [Related]
27. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study. Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725 [TBL] [Abstract][Full Text] [Related]
28. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Angel LF; Cai TH; Sako EY; Levine SM Ann Transplant; 2000; 5(3):26-30. PubMed ID: 11147026 [TBL] [Abstract][Full Text] [Related]
29. Impact of the posttransplant lymphoproliferative disorder subtype on survival. Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330 [TBL] [Abstract][Full Text] [Related]
32. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study. OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265 [TBL] [Abstract][Full Text] [Related]
33. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Aull MJ; Buell JF; Trofe J; First MR; Alloway RR; Hanaway MJ; Wagoner L; Gross TG; Beebe T; Woodle ES Transplantation; 2004 Dec; 78(11):1676-82. PubMed ID: 15591959 [TBL] [Abstract][Full Text] [Related]
34. Outcomes of kidney retransplantation in recipients with prior posttransplant lymphoproliferative disorders: An analysis of the 2000-2019 UNOS/OPTN database. Leeaphorn N; Thongprayoon C; Chewcharat A; Hansrivijit P; Jadlowiec CC; Cummings LS; Katari S; Mao SA; Mao MA; Cheungpasitporn W Am J Transplant; 2021 Feb; 21(2):846-853. PubMed ID: 33128832 [TBL] [Abstract][Full Text] [Related]
35. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761 [TBL] [Abstract][Full Text] [Related]
36. Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review. Stanley K; Friehling E; Ranganathan S; Mazariegos G; McAllister-Lucas LM; Sindhi R Pediatr Transplant; 2018 Aug; 22(5):e13211. PubMed ID: 29745058 [TBL] [Abstract][Full Text] [Related]
37. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. Gautam A; Morrissey PE; Brem AS; Fischer SA; Gohh RY; Yango AF; Monaco AP Pediatr Transplant; 2006 Aug; 10(5):613-6. PubMed ID: 16856999 [TBL] [Abstract][Full Text] [Related]
38. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ; Homan van der Heide JJ; Veeger NJ; Kluin PM; Kluin-Nelemans HC Clin Transplant; 2005 Jun; 19(3):327-34. PubMed ID: 15877793 [TBL] [Abstract][Full Text] [Related]
39. Increased beta 2-microglobulin (B2M) is useful in the detection of post-transplant lymphoproliferative disease (PTLD). Sasaki TM; Pirsch JD; D'Alessandro AM; Knechtle SJ; Kalayoglu M; Hafez GR; Sollinger HW Clin Transplant; 1997 Feb; 11(1):29-33. PubMed ID: 9067691 [TBL] [Abstract][Full Text] [Related]